Health news
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate and taurursodiol) for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is an oral, fixed-dose…
A phase 3 trial evaluating ravulizumab (Ultomiris) in adults with amyotrophic lateral sclerosis (ALS) has been discontinued. The multicenter, randomized, double-blind, placebo-controlled CHAMPION-ALS trial (ClinicalTrials.gov Identifier: NCT04248465) evaluated the efficacy and safety of ravulizumab, a…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021